Archivio di Ortopedia e Reumatologia

, Volume 119, Issue 3–4, pp 28–30

L’aderenza alle terapie per l’osteoporosi: l’esempio dei bisfosfonati

  • S. Casari
  • L. Sinigaglia
Articolo su Invito

Adherence to osteoporosis therapy: the example of bisphosphonates


Bisphosphonates are the most potent and effective inhibitors of bone resorption in clinical use, with good efficacy and tolerability in reducing fracture risk, in increasing bone mineral density and in reducing biochemical markers of bone turnover. Clinical trials indicate that bisphosphonates can reduce the incidence of fractures related to postmenopausal osteoporosis but adherence to bisphosphonate therapy remains suboptimal. Long-term adherence with bisphosphonates is required for optimal and sustained therapeutic benefits in postmenopausal osteoporosis. Simplifying dosing by reducing the frequency and/or number of administrations is an often-used strategy for enhancing adherence, especially with new compounds with high anti-resorptive potency and favourable bone-binding properties


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353:487–497PubMedCrossRefGoogle Scholar
  2. 2.
    McDonnell PJ, Jacobs MR (2002) Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 36:1331–1336PubMedCrossRefGoogle Scholar
  3. 3.
    Senst BL, Achusim LE, Genest RP et al (2001) Practical approach to determining costs and frequency of adverse drug events in a health care network. Am J Health Syst Pharm 58:1126–1132PubMedGoogle Scholar
  4. 4.
    Levy G, Zamacona MK, Jusko WJ (2000) Developing compliance instructions for drug labeling. Clin Pharmacol Ther 68:586–591PubMedCrossRefGoogle Scholar
  5. 5.
    Berg JS, Dischler J, Wagner DJ et al (1993) Medication compliance: a healthcare problem. Ann Pharmacother 27[9 Suppl.]:1–24Google Scholar
  6. 6.
    Claxton AJ, Cramer J, Pierce C (2001) A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23:1296–1310PubMedCrossRefGoogle Scholar
  7. 7.
    Tosteson AN, Grove MR, Hammond CS et al (2003) Early discontinuation of treatment for osteoporosis. Am J Med 115:209–216PubMedCrossRefGoogle Scholar
  8. 8.
    Segal E, Tamir A, Ish-Shalom S (2003) Compliance of osteoporotic patients with different treatment regimens. Isr Med Assoc J 5:859–862PubMedGoogle Scholar
  9. 9.
    Turbi C, Herrero-Beaumont G, Acebes JC (2004) Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study. Clin Ther 26:245–256PubMedCrossRefGoogle Scholar
  10. 10.
    Lombas C, Hakim C, Zanchetta JR (2001) Compliance with alendronate treatment in an osteoporosis clinic. J Bone Miner Res 15[Suppl 1]:529Google Scholar
  11. 11.
    McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271–287PubMedCrossRefGoogle Scholar
  12. 12.
    Rossini M, Bianchi G, Di Munno O et al (2006) Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 17:914–921PubMedCrossRefGoogle Scholar
  13. 13.
    Eastell R, Garnero P, Vrijens B et al (2003) Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the IMPACT study. Calcif Tissue Int 72:408Google Scholar
  14. 14.
    Sebaldt RJ, Shane LG, Pham B et al (2004) Longer term effectiveness outcomes of non-compliance and nonpersistence with daily regimen bisphosphonate therapy in patients with osteoporosis treated in tertiary specialist care. Osteoporos Int 15[Suppl. 1]:107Google Scholar
  15. 15.
    Yood RA, Emani S, Reed JI et al (2003) Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 14:965–968PubMedCrossRefGoogle Scholar
  16. 16.
    Caro JJ, Ishak KJ, Huybrechts KF et al (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003–1008PubMedCrossRefGoogle Scholar
  17. 17.
    Sambrook PN (2002) Glucocorticoid osteoporosis. Curr Pharm Des 8:1877–1883PubMedCrossRefGoogle Scholar
  18. 18.
    Roux C, Dougados M (1999) Treatment of patients with Paget’s disease of bone. Drugs 58:823–830PubMedCrossRefGoogle Scholar
  19. 19.
    Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165–176PubMedCrossRefGoogle Scholar
  20. 20.
    Sinigaglia L, Varenna M, Casari S (2007) Pharmacokinetic profile of bisphosphonates in the treatment of metabolic bone disorders. Clinical Cases in Mineral and Bone Metabolism 4:30–36Google Scholar
  21. 21.
    Stenbeck G, Horton MA (2000) A new specialized cell-matrix interaction in actively resorbing osteoclasts. J Cell Sci 113:1577–1587PubMedGoogle Scholar
  22. 22.
    Mönkkönen H, Rogers MJ, Makkonen N et al (2001) The cellular uptake and metabolism of clodronate in RAW 264 macrophages. Pharm Res 18:1550–1555PubMedCrossRefGoogle Scholar
  23. 23.
    Rogers MJ (2003) New insights into the molecular mechanisms of actions of bisphosphonates. Curr Pharm Des 9:2643–2658PubMedCrossRefGoogle Scholar
  24. 24.
    Etienne-Manneville S, Hall A (2002) Rho GTPases in cell biology. Nature 420:629–635PubMedCrossRefGoogle Scholar
  25. 25.
    Zerial M, McBride H (2001) Rab proteins as membrane organizers. Nat Rev Mol Cell Biol 2:107–117PubMedCrossRefGoogle Scholar
  26. 26.
    Coleman Ml, Olson MF (2002) Rho GTPase signalling pathways in the morphological changes associated with apoptosis. Cell Death Differ 9:493–504PubMedCrossRefGoogle Scholar
  27. 27.
    Coxon FP, Rogers MJ (2003) The role of prenylated small GTP-binding proteins in the regulation of osteoclast function. Calcif Tissue Int 72:80–84PubMedCrossRefGoogle Scholar
  28. 28.
    Dunford JE, Thompson K, Coxon FP et al (2001) Structure-activity relationships for inhibiton of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296:235–242PubMedGoogle Scholar
  29. 29.
    van Beek E, Hoekstra M, van de Ruit M et al (1994) Structural requirements for bisphosphonate actions in vitro. J Bone Miner Res 9:1875–1882PubMedCrossRefGoogle Scholar
  30. 30.
    van Beek ER, Löwik CW, Ebetino FH, Papapoulos SE (1998) Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: structure-activity relationships. Bone 23:437–442PubMedCrossRefGoogle Scholar
  31. 31.
    Nancollas GH, Tang R, Phipps RJ et al (2006) Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38:617–627PubMedCrossRefGoogle Scholar
  32. 32.
    Cremers SC, Pillai G, Papapoulos SE (2005) Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet 44:551–570PubMedCrossRefGoogle Scholar
  33. 33.
    Redalieu E, Coleman JM, Chan K et al (1993) Urinary excretion of aminohydroxypropylidene bisphosphonate in cancer patients after single intravenous infusions. J Pharm Sci 82:665–667PubMedCrossRefGoogle Scholar
  34. 34.
    Chen T, Berenson J, Vescio R et al (2002) Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 42:1228–1236PubMedCrossRefGoogle Scholar
  35. 35.
    Watts N, Olszynski WP, McKeever CD et al (2004) Treatment discontinuation effects on bone turnover and BMD with risedronate. Bone 34[Suppl. 1]:99Google Scholar
  36. 36.
    Bone HG, Hosking D, Devogelaer JP et al (2004) Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189–1199PubMedCrossRefGoogle Scholar
  37. 37.
    Fairney A, Kyd P, Thomas E, Wilson J (1998) The use of cyclical etidronate in osteoporosis: changes after completion of 3 years treatment. Br J Rheumatol 37:51–56PubMedCrossRefGoogle Scholar
  38. 38.
    Reid IR, Brown JP, Burckhardt P et al (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653–656PubMedCrossRefGoogle Scholar
  39. 39.
    Khan SA, Kanis JA, Vasikaran S et al (1997) Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 12:1700–1707PubMedCrossRefGoogle Scholar
  40. 40.
    Recker RR, Gallagher R, Mac-Cosbe PE (2005) Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 80:856–861PubMedCrossRefGoogle Scholar
  41. 41.
    Cooper A, Drake J, Brankin E (2006) Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 60:896–905PubMedCrossRefGoogle Scholar
  42. 42.
    Fraenkel L, Gulanski B, Wittink D (2006) Patient treatment preferences for osteoporosis. Arthritis Rheum 55:729–735PubMedCrossRefGoogle Scholar
  43. 43.
    Schnitzer T, Bone HG, Crepaldi G et al (2000) Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 12:1–12Google Scholar
  44. 44.
    Brown JP, Kendler DL, McClung MR et al (2002) The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 71:103–111PubMedCrossRefGoogle Scholar
  45. 45.
    Chesnut CH, Skag A, Christiansen C et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241–1249CrossRefGoogle Scholar
  46. 46.
    Delmas PD, McClung MR, Zanchetta JR et al (2008) Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone 42:36–42PubMedCrossRefGoogle Scholar
  47. 47.
    Delmas PD, Adami S, Strugala C et al (2006) Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 54:1838–1846PubMedCrossRefGoogle Scholar
  48. 48.
    Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2009

Authors and Affiliations

  • S. Casari
    • 1
  • L. Sinigaglia
    • 1
  1. 1.U.O.C.Day Hospital di ReumatologiaIstituto Ortopedico G.PiniMilanoItaly

Personalised recommendations